| Products/Services Used | Details | Operation |
|---|---|---|
| Peptide Synthesis | single cell suspensions of lymph nodes were re-stimulated ex vivo with antigen-loaded APCs (details see below) or OVA protein (20 μg/ml, Sigma Aldrich) plus MHC class II OVA323–339 peptide (5 μM, GenScript) for 2 h in R10 at 37 °C in 5% CO2 followed by 5 μg/mL Brefeldin A (Sigma Aldrich) treatment for 4 h. Floating cells were harvested and incubated with B16-OVA TCL, MC38 TCL, MHC class I OVA257–264 peptide (GenScript), | Get A Quote |
The potential of dendritic cell (DC) vaccination against cancer is not fully achieved. Little is known about the precise nature of the anti-cancer immune response triggered by different natural DC subsets and their relevance in preventing postsurgical tumor recurrence. Here, we use mouse splenic conventional DC1s (cDC1s) or cDC2s pulsed with tumor cell lysates to generate DC vaccines. cDC1-based vaccination induces a stronger effector and memory CD4+ and CD8+ anti-tumor T cell response, leading to a better control of tumors treated either therapeutically or prophylactically. Using an experimental model of tumor relapse, we show that adjuvant or neoadjuvant cDC1 vaccination improves anti-tumor immune memory, par... More
